FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024263745> ?p ?o ?g. }

• W2024263745 endingPage "241" @default.
• W2024263745 startingPage "235" @default.
• W2024263745 abstract "Background & Aims Single nucleotide polymorphisms (SNPs) near the interferon lambda 3 (IFNL3, previously known as IL28B) region are the strongest baseline predictors of sustained virologic response (SVR) to pegylated interferon and ribavirin therapy in hepatitis C virus (HCV) genotype 1 infection. Whether IFNL3 SNPs influence treatment response in genotype 2 and 3 (HCV-2/3) infection remains controversial. This study sought to clarify in a large cohort, whether SNPs in the IFNL3 region are associated with treatment response in HCV-2/3 patients. Methods The cohort comprised 1002 HCV-2/3 Caucasians patients treated with pegylated interferon-alpha and ribavirin who underwent genotyping for the SNPs rs12979860 and rs8099917. Results Overall, 736 (73.5%) patients achieved SVR (81.9%, 67.9%, and 57.8% for rs12979860 CC, CT, and TT [p = 0.0001]; 78%, 68.7%, and 46.3% for rs8099917 TT, TG, and GG [p = 0.0001]). By logistic regression, both rs12979860 CC and rs8099917 TT were independent predictors of SVR with an odds ratio (OR) of 2.39 (1.19–3.81) p = 0.0001 and OR 1.85 (1.15–2.23) p = 0.0001, respectively. IFNL3 responder genotypes were more frequent in relapsers than null-responders (p = 0.0001 for both SNPs). On-treatment rapid virological response (RVR) was predictive of SVR only in those individuals with IFNL3 non-responder genotypes (rs12979860 CT/TT and rs8099917 TG/GG). Conclusions This adequately powered study in patients with HCV genotypes 2 or 3 infection clearly demonstrates that IFNL3 genotypes are the strongest baseline predictor of SVR, in keeping with the known association for genotype 1 infection. IFNL3 genotyping can aid in therapeutic decision making for these patients. Single nucleotide polymorphisms (SNPs) near the interferon lambda 3 (IFNL3, previously known as IL28B) region are the strongest baseline predictors of sustained virologic response (SVR) to pegylated interferon and ribavirin therapy in hepatitis C virus (HCV) genotype 1 infection. Whether IFNL3 SNPs influence treatment response in genotype 2 and 3 (HCV-2/3) infection remains controversial. This study sought to clarify in a large cohort, whether SNPs in the IFNL3 region are associated with treatment response in HCV-2/3 patients. The cohort comprised 1002 HCV-2/3 Caucasians patients treated with pegylated interferon-alpha and ribavirin who underwent genotyping for the SNPs rs12979860 and rs8099917. Overall, 736 (73.5%) patients achieved SVR (81.9%, 67.9%, and 57.8% for rs12979860 CC, CT, and TT [p = 0.0001]; 78%, 68.7%, and 46.3% for rs8099917 TT, TG, and GG [p = 0.0001]). By logistic regression, both rs12979860 CC and rs8099917 TT were independent predictors of SVR with an odds ratio (OR) of 2.39 (1.19–3.81) p = 0.0001 and OR 1.85 (1.15–2.23) p = 0.0001, respectively. IFNL3 responder genotypes were more frequent in relapsers than null-responders (p = 0.0001 for both SNPs). On-treatment rapid virological response (RVR) was predictive of SVR only in those individuals with IFNL3 non-responder genotypes (rs12979860 CT/TT and rs8099917 TG/GG). This adequately powered study in patients with HCV genotypes 2 or 3 infection clearly demonstrates that IFNL3 genotypes are the strongest baseline predictor of SVR, in keeping with the known association for genotype 1 infection. IFNL3 genotyping can aid in therapeutic decision making for these patients." @default.
• W2024263745 created "2016-06-24" @default.
• W2024263745 creator A5003299584 @default.
• W2024263745 creator A5011865871 @default.
• W2024263745 creator A5013141366 @default.
• W2024263745 creator A5015078382 @default.
• W2024263745 creator A5020720433 @default.
• W2024263745 creator A5022914731 @default.
• W2024263745 creator A5028263779 @default.
• W2024263745 creator A5029766894 @default.
• W2024263745 creator A5033387814 @default.
• W2024263745 creator A5034809536 @default.
• W2024263745 creator A5039389628 @default.
• W2024263745 creator A5043335344 @default.
• W2024263745 creator A5053988869 @default.
• W2024263745 creator A5058075133 @default.
• W2024263745 creator A5058541785 @default.
• W2024263745 creator A5058633927 @default.
• W2024263745 creator A5062291206 @default.
• W2024263745 creator A5071565406 @default.
• W2024263745 creator A5084947428 @default.
• W2024263745 date "2014-08-01" @default.
• W2024263745 modified "2023-10-17" @default.
• W2024263745 title "IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection" @default.
• W2024263745 cites W1976745213 @default.
• W2024263745 cites W1981036435 @default.
• W2024263745 cites W1981066923 @default.
• W2024263745 cites W1983573952 @default.
• W2024263745 cites W1987959316 @default.
• W2024263745 cites W1993009549 @default.
• W2024263745 cites W2013607338 @default.
• W2024263745 cites W2017013905 @default.
• W2024263745 cites W2026614040 @default.
• W2024263745 cites W2028907784 @default.
• W2024263745 cites W2063285149 @default.
• W2024263745 cites W2071277949 @default.
• W2024263745 cites W2073113951 @default.
• W2024263745 cites W2078543656 @default.
• W2024263745 cites W2082572940 @default.
• W2024263745 cites W2085261733 @default.
• W2024263745 cites W2086409213 @default.
• W2024263745 cites W2086414517 @default.
• W2024263745 cites W2093977114 @default.
• W2024263745 cites W2094174828 @default.
• W2024263745 cites W2112876622 @default.
• W2024263745 cites W2127685726 @default.
• W2024263745 cites W2143374555 @default.
• W2024263745 cites W2157961528 @default.
• W2024263745 cites W2160334536 @default.
• W2024263745 cites W2222306685 @default.
• W2024263745 cites W4247506833 @default.
• W2024263745 doi "https://doi.org/10.1016/j.jhep.2014.03.039" @default.
• W2024263745 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24768758" @default.
• W2024263745 hasPublicationYear "2014" @default.
• W2024263745 type Work @default.
• W2024263745 sameAs 2024263745 @default.
• W2024263745 citedByCount "35" @default.
• W2024263745 countsByYear W20242637452014 @default.
• W2024263745 countsByYear W20242637452015 @default.
• W2024263745 countsByYear W20242637452016 @default.
• W2024263745 countsByYear W20242637452017 @default.
• W2024263745 countsByYear W20242637452018 @default.
• W2024263745 countsByYear W20242637452019 @default.
• W2024263745 countsByYear W20242637452020 @default.
• W2024263745 crossrefType "journal-article" @default.
• W2024263745 hasAuthorship W2024263745A5003299584 @default.
• W2024263745 hasAuthorship W2024263745A5011865871 @default.
• W2024263745 hasAuthorship W2024263745A5013141366 @default.
• W2024263745 hasAuthorship W2024263745A5015078382 @default.
• W2024263745 hasAuthorship W2024263745A5020720433 @default.
• W2024263745 hasAuthorship W2024263745A5022914731 @default.
• W2024263745 hasAuthorship W2024263745A5028263779 @default.
• W2024263745 hasAuthorship W2024263745A5029766894 @default.
• W2024263745 hasAuthorship W2024263745A5033387814 @default.
• W2024263745 hasAuthorship W2024263745A5034809536 @default.
• W2024263745 hasAuthorship W2024263745A5039389628 @default.
• W2024263745 hasAuthorship W2024263745A5043335344 @default.
• W2024263745 hasAuthorship W2024263745A5053988869 @default.
• W2024263745 hasAuthorship W2024263745A5058075133 @default.
• W2024263745 hasAuthorship W2024263745A5058541785 @default.
• W2024263745 hasAuthorship W2024263745A5058633927 @default.
• W2024263745 hasAuthorship W2024263745A5062291206 @default.
• W2024263745 hasAuthorship W2024263745A5071565406 @default.
• W2024263745 hasAuthorship W2024263745A5084947428 @default.
• W2024263745 hasConcept C104317684 @default.
• W2024263745 hasConcept C126322002 @default.
• W2024263745 hasConcept C135763542 @default.
• W2024263745 hasConcept C151956035 @default.
• W2024263745 hasConcept C153209595 @default.
• W2024263745 hasConcept C156957248 @default.
• W2024263745 hasConcept C203014093 @default.
• W2024263745 hasConcept C2522874641 @default.
• W2024263745 hasConcept C2776408679 @default.
• W2024263745 hasConcept C2776455275 @default.
• W2024263745 hasConcept C2776461080 @default.
• W2024263745 hasConcept C2780040827 @default.
• W2024263745 hasConcept C31467283 @default.
• W2024263745 hasConcept C54355233 @default.

• next